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Prostate cancer is the second most common malignancy, and the fifth leading cause of cancer 
related death among men, worldwide. A major unsolved clinical challenge in prostate cancer 
is the ability to accurately distinguish indolent cancer types from the aggressive ones. 
Reprogramming of metabolism is now a widely accepted hallmark of cancer development, 
where cancer cells must be able to convert nutrients to biomass while maintaining energy 
production. Metabolomics is the large-scale study of small molecules, commonly known as 
metabolites, within cells, biofluids, tissues or organisms. Nuclear magnetic resonance (NMR) 
spectroscopy  is commonly applied in metabolomics studies of cancer. This chapter provides 
protocols for NMR-based metabolomics of cell cultures, biofluids (serum and urine) and 
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Prostate cancer is the second most common malignancy, and the fifth leading cause of cancer 
related death among men, worldwide [1]. Prostate cancer is a manifested heterogeneous 
disease, ranging from slow growing and indolent to aggressive with high risk of fatal 
outcome. A major unsolved clinical challenge in prostate cancer is the ability to accurately 
distinguish indolent cancer types from the aggressive ones. This leads to substantial 
overtreatment of patients with harmless cancers, as well as undertreatment of patients with 
aggressive disease.  
Reprogramming of metabolism is now a widely accepted hallmark of cancer development [2]. 
Cancer cells must be able to convert nutrients to biomass while maintaining energy 
production, which requires reprogramming of central metabolic processes in the cells. This 
phenomenon is increasingly recognized as a potential target for treatment, but also as a source 
for biomarkers that can be used for prognosis, risk stratification and therapy monitoring. 
Metabolomics is the large-scale study of small molecules, commonly known as metabolites, 
within cells, biofluids, tissues or organisms. Collectively, these small molecules and their 
interactions within a biological system are known as the metabolome. Since metabolites not 
only represent the downstream output of the genome, but also the upstream input from the 
tumor microenvironment, they contain a rich source of information that is currently 
underexploited. Metabolomics have shown that prostate cancer cells display significantly 
altered metabolism compared to normal cells [3, 4]. It has repeatedly been shown that 
distinctive metabolites are associated with prostate cancer aggressiveness and recurrence, and 
further that these metabolites are associated with gene regulation of cancer-associated 




Nuclear magnetic resonance (NMR) spectroscopy  is one of the most widely applied 
methodologies in metabolomics studies of cancer, using sample material such as cell culture 
extracts, biofluids or even intact tissue [10]. NMR spectroscopy is a robust and reproducible 
technique with safe metabolite identification, requiring limited sample preparation leaving the 
sample intact after analysis. Additionally, in conjunction with the use of stable isotope 
tracers, NMR spectroscopy is an excellent method for exploring the dynamics and 
compartmentation of metabolic pathways and networks. The major limitation compared to 
mass spectrometry (MS) is the lower sensitivity (micromolar range compared to picomolar 
range for some MS-based methods), however, metabolites from important cancer pathways 
(glycolysis, choline metabolism, amino acids) are detected by MR analysis. The aim of the 
current chapter is to provide protocols for NMR-based metabolomics of cell cultures, 
biofluids (serum and urine) and intact tissue, with concurrent advice for optimal biobanking 
and sample preparation procedures.  
2. Materials 
All work in the laboratory should be carried out wearing a lab coat and disposable gloves 
when handling chemical reagents and biological material. When handling liquid nitrogen, 
safety glasses and cryo-gloves, lab coat with long sleeves, and pants worn outside the shoes to 
prevent shoes from filling should be worn. Chloroform and methanol must be handled in a 
ventilated fume hood. 
2.1. Biobanking 
2.1.1. Biofluids collection 
1. For serum: Hypodermic needles, serum-separating tubes, pipettes, and cryo-
compatible tubes. 
2. For urine: Sterile urine containers, pipettes and cryo-compatible tubes.  
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3. Centrifuge and -80 °C freezer. 
2.1.2. Tissue 
1. Biopsy needle and scalpel or double bladed knife. 
2. Cryo-compatible container, tube or bag. 
3. Two solid metal plates (thickness ≥ 5mm), metal plate with a pit suitable for drilling, 
drill fixed to a stand, bits for drill to cut out cylinders, tweezers and styrofoam surface.  
4. Liquid nitrogen and nitrogen-compatible thermos. 
2.2. Biofluids analysis 
1. Eppendorf tubes, 3mm NMR tubes with caps, syringes with long needles (>10 cm), 
micropipette(s) (60-550µL) and tips, and ruler for serum analysis. 
2. Vortex or shaker and centrifuge.  
3. Buffer solutions for serum (See Note 1) and/or urine analysis (See Note 2). 
2.3. Polar cell extract analysis 
1. Pipette(s), T225 flasks, tubes and cell scrapers. 5 mm NMR tubes with caps. 
2. Sterile cell culture medium (See Note 3), phosphate buffered saline (PBS), D2O 
(99.8%)-based PBS solution, 70% methanol and ice. 
3. Centrifuge, vortex and -80°C freezer. 
4. Parafilm, 27G-30G needles and a lyophilizer for freeze-drying of cell extracts. 
2.4. Dual phase tissue extract analysis 
1. Cryo-comaptible tubes (2 mL and 15 mL), pipettes, ice cooled porcelain mortar and 
pestile and spatula. 5 mm NMR tubes with caps. 
2. Methanol (-20°C), chloroform (-20°C), liquid nitrogen and distilled water (ice cold). 
3. Analytical balance, vortex, centrifuge and lyophilizer. 
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2.5. Intact tissue analysis 
1. Rotors with caps, disposable inserts, plugs and screws, filling funnel and screw driver. 
2. Micropipette and tips, tweezers, weighing boats and permanent marker. 
3. 25 mM sodium formate (HCOONa) in D2O (99.8%) solution and liquid nitrogen.  
4. Analytical balance and a cooled work station (described in [11]) or ice block.  
3. Methods 
3.1. Biobanking: Collection and storage of biological material 
Human biological material is regularly collected and stored in biobanks across the world. The 
stored material may include tissue, full blood, serum, plasma and urine. This collection plays 
a crucial role in modern biomedical research. For any biobank it is of utmost importance to 
have standardized protocols for handling biological material, to ensure reproducibility in 
research projects. Biobanks also have a responsibility to strictly adhere to national and 
international ethical guidelines regarding patient consent, privacy and safety of donors and 
proper archiving of samples.  
3.1.1. Biofluids 
Biofluids include full blood, serum, plasma and urine. Blood and urine should be collected in 
the morning after a fasting night, unless the research question requires other collection 
conditions. 
Serum 
For NMR experiments, serum is preferred over whole blood and plasma, as the latter two 
contain cells, clotting factors and additives which can interact with metabolites of the sample 
[12]. Serum can be separated from whole blood through centrifugation in serum-separating 
tubes or sedimentation with EDTA. Serum separating tubes includes a gel which 
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fractionalizes and accelerates blood clotting. This method is preferred over sedimentation, as 
EDTA is a contaminant for NMR analysis (See Note 4). 
Protocol for serum 
1. Collect venous blood from the donor in a serum separating tube with a hypodermic 
needle (This step has to be performed by an official health care professional). 
2. After collection, invert the tube five times to mix the sample with the gel included in 
the serum separating tube. 
3. Leave the sample at room temperature for 30 minutes for coagulation to occur. 
4. Centrifuge the blood sample at 1800 x g for 10 minutes. 
5. Carefully transfer the top layer of supernatant to one or more cryo-compatible tubes 
using a pipette (See Note 5). 
6. The serum samples can be used immediately (continue at subheading 3.2.1, Protocol 
for serum, step 2), or placed in a -80 °C freezer. 
Urine 
Urine is a true non-invasive way of biological sampling and does not require the competence 
of a health care professional for collection. 
Protocol for urine 
1. The urine is collected by the donors themselves in a sterile urine container and closed 
with the screw lid 
2. Pipette appropriate volumes of urine from the urine container into cryo-compatible 
tubes. 
3. The urine samples can be used immediately (continue at subheading 3.2.1, Protocol 
for urine, step 2) or placed in a -80 °C freezer (See Note 6).  
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4. Before analysis, large containers may be thawed overnight in the fridge and 
centrifugation may be needed to remove precipitation.   
3.1.2. Tissue 
Prostate cancer tissue is more difficult to collect compared to biofluids due to the limited 
amount of material and the unavoidable invasiveness of the procedure. However, tissue offers 
a more direct and valuable view into the metabolism of the tumor. Tissue from the prostate 
can either be collected as transrectal needle biopsies directly from the patient, as surgical 
biopsies after radical prostatectomy or as thin tissue slices after radical prostatectomy [13]. To 
stop tissue degradation, the material has to be snap frozen as fast as possible but within 30 
minutes after blood supply is cut to  [14, 15]. 
Protocol for needle biopsies 
1. Collect the tissue with a sterile biopsy needle (This step has to be performed by a 
health care professional). 
2. Place the biopsy in a cryo-compatible tube with a clean tweezer. Drop the closed tube 
in liquid nitrogen and store the sample in either -80 °C or keep in liquid nitrogen. 
3. Before NMR analysis, place the biopsy on a plastic weighing boat on top of a metal 
plate, which has been pre-cooled in liquid nitrogen, and use a scalpel to cut off 
approximately 1 mm at each end (See Note 7). 
Tissue slice collection  
This protocol is adapted from a highly standardized biobank collection of 2 mm research 
slices from the middle of the resected prostate. A homemade drilling system is developed for 




Protocol for tissue slice collection 
1. After surgical removal of the prostate, extract a complete prostate tissue slice by 
placing the prostate in a holder with a double bladed knife [13]. 
2. Place the tissue slice in a pre-cooled cryo-clamp to prevent tissue bulging. 
3. Plunge the cryo-clamp with the tissue into liquid nitrogen.  
4. Transfer the frozen tissue into a cryo-compatible bag or other container and place it in 
a -80 °C freezer. 
Protocol for tissue cylinder drilling from 2 mm whole-mount tissue slices (See Note 8) 
1. Pre-cool metal plates (designed for drilling) by placing them in liquid nitrogen 
using cryo-glowes. The metal is sufficiently cooled down when the nitrogen has 
stopped boiling. 
2. Take out the metal plates from the liquid nitrogen using cryo-gloves and place 
them on the styrofoam surface. 
3. Before proceeding to subheading 3.2.4, Protocol for intact tissue, place the 
tissue slice on the metal plate. Hold the tissue stable and drill out cylinders (1-3 
mm diameters) (See Note 9). 
4. Optional: The drilled sample may be cryo-sectioned and stained to obtain a 
histopathological evaluation of the sample before using it for analyses. Use 
isotonic saltwater for fixating the sample during sectioning to avoid contamination 
of your sample (See Note 10). 
5. In order to fit the sample into the insert, cut the cylinder into smaller pieces with a 
biopsy core device or scalpel as described in subheading 3.1.2, Protocol for 
needle biopsies, step 3. 
10 
 
3.2. Sample preparation  
3.2.1. Biofluids  
Liquid biopsies are easy to access and less invasive than tissue biopsies. The metabolic 
profiles of biofluids such as serum and urine can be investigated by NMR spectroscopy in a 
quantitative, automated and high-throughput fashion.  
Protocol for serum 
1. Thaw samples at room temperature (See Note 11). 
2. Slowly invert the tubes containing the thawed serum sample a couple of times to mix. 
3. Pipette an equal volume (≥120 µL) of serum (See Note 12) and serum buffer (See 
Note 1) into an Eppendorf tube. Slowly invert the tube three times to create a 
homogenous 50:50 serum:buffer mix. 
4. Mark a 3mm NMR tube at a height of 4 cm, excluding the curved bottom from the 
measurement. 
5. Use a long needle and syringe to fill the NMR tube with the serum:buffer mix to the 4 
cm mark without air bubbles. 
6. Cap the NMR tube by pressing the cap against the tube with your index finger until a 
click is heard. 
Protocol for urine   
1. Thaw samples at room temperature (See Note 11). 
2. Centrifuge the samples at 3000 x g for five minutes to remove debris. 
3. Pipette 540 µL of urine and 60 µL of urine buffer (See Note 2) into an Eppendorf 
tube. Mix using vortex or shake. 
4. Use a long needle and syringe to fill the NMR tube with the urine:buffer mix without 
air bubbles. This should fill the NMR tubes at exactly 4 cm. 
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5. Continue at subheading 3.2.1, Protocol for serum, step 6. 
3.2.2. Cell extracts 
For in vitro metabolomics studies, extracts of cultured cancer cells can be prepared for 
analysis using high-resolution NMR spectroscopy (See Note 13). The choice of extraction 
protocol depends on the polarity and cellular concentration of the metabolites of interest. 
Below, we describe a protocol that allows analysis of culture medium and polar cell extracts 
from experiments where cells have been cultured with a 13C-enriched substrate (See Note 14) 
for targeted studies of specific metabolic reactions (See Note 15). It should be noted that the 
choice of 13C tracer, cell line, culture medium composition and experimental conditions 
depend on the objective of the experiment. It is, however, important to select the total number 
of cells, substrate concentration and incubation time so that the amount of 13C substrate 
consumed by the cells will give sufficiently high signal-to-noise ratio in the NMR spectra in 
an acceptable experiment time. 
Protocol for polar cell extraction 
1. Culture approximately 1.5 x 107 cells to roughly 70% confluency in T225 flasks. 
2. At T0, replace medium with 40 mL fresh culture medium-containing tracer of choice. 
3. Transfer 2 mL of the culture medium to a centrifuge tube and store at -80°C. 
4. At time of harvest (See Note 16), collect 2 mL spent culture medium in cryo-
compatible  tubes and immediately store in -80°C. 
5. Wash cells twice with 25 mL PBS. 
6. Place 25 mL of -20°C 70% methanol on cells. 
7. Using a cell scraper, remove cells off flask bottom, transfer them to a centrifuge tube 
and store on ice. 
8. Vortex for 5 minutes. 
9. Repeat steps 6-7, transferring to a separate cryo-compatible tube. 
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10. Repeat step 8. 
11. Centrifuge extract tubes at 18000 x g for 15 minutes at 4°C.  
12. Pool the metabolite extracts from the two tubes (for each sample) to one 50 mL tube 
and store at -80°C. Store cell debris pellets at -80°C for determination of total protein 
content (See Note 17). 
13. Additional control samples can be prepared according to steps 1-10 to compensate for 
naturally abundant 13C: 
-Extracts from cells cultured in the absence of 13C labeled tracer  
-Fresh and used culture medium (without 13C substrate) 
 
Culture medium and cell extracts should be stored at -80°C until further analysis. Cell extracts 
must be freeze-dried and reconstituted in a small volume of NMR-compatible buffer before 
analysis, whereas culture media can be analyzed directly after addition of a small amount of 
NMR-compatible buffer. 
 
Protocol for freeze-drying of cell extracts 
1. Distribute cold (-80°C) cell extracts into 50 mL tubes in small volumes (5-10 mL) in 
each tube. 
2. Put parafilm on the top of each open tube and pierce/stick the parafilm 20-25 times 
with a needle.  
3. Freeze dry the sample until all liquid has evaporated (typically takes several hours). 
Store at -80°C. 
 
Protocol for NMR sample preparation of polar cell extracts 
1. Dissolve the metabolite pellet thoroughly in 700 µL PBS dissolved in D2O.  
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2. Centrifuge at 2300 x g (4°C ) for 10 minutes. On visual inspection, the reconstituted 
sample should be clear and free from particles.  
3. Using a pipette, transfer 600 µL of the supernatant into 5 mm NMR tubes for NMR 
acquisition. 
Protocol for preparation of culture medium prior to NMR acquisition 
1. Centrifuge the culture medium at 2300 x g for 10 minutes. On visual inspection, the 
sample should be clear and free from particles. 
2. Mix 500 µL of medium with 100 µL PBS in D2O 
3. Using a pipette, transfer the solution (600uL) into 5 mm NMR tubes for NMR 
acquisition. 
 
3.2.3. Tissue extracts 
Chemical extractions can be performed on prostate tissue to yield solutions enriched with 
tissue metabolites that can be analyzed with high resolution NMR spectroscopy in the same 
way as biofluids and cell extracts. The extraction method should be chosen according to the 
polarity of the metabolites of interest. For example, for extraction of polar metabolites only, 
extraction protocols based on perchloric acid can be used. Below we describe a dual-phase 
extraction procedure using methanol and chloroform. This procedure yields two fractions that 
can be analyzed with NMR separately: an aqueous (polar) phase, containing water-soluble 
low-molecular weight metabolites, and an organic phase containing non-polar lipophilic 
molecules.  
Protocol for dual-phase tissue extraction 
1. Weigh the tissue on a weighing boat with an analytical balance and register the weight 
(See Note 18). 
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2. Crush and grind the tissue into a fine powder in liquid nitrogen using a pre-cooled 
mortar and pestile. 
3. Using a pre-cooled spatula, transfer the powder into a 2mL cryo-compatible tube 
sitting on ice, which will be referred to as tube 1.  
4. Add three times the tissue weight in cold methanol into tube 1. 
5. Add ca 100 µL of water into tube 1. 
6. Add six times the tissue weight in cold chloroform into tube 1 (See Note 19). 
7. Vortex until a milky appearance is achieved. 
8. Centrifuge tube 1 at 4°C at 1800 x g for 15 minutes. 
9. Using a pipette, transfer the resulting top layer, i.e. the polar methanol phase, to a new 
cryo-compatible tube, which will be referred to as tube 2 (See Note 20). Keep tube 2 
on ice. 
10. Add six times the tissue weight in methanol, four times the tissue weight in water and 
four times the tissue weight in chloroform into tube 1 and vortex. 
11. Repeat steps 8 and 9. 
12. Add three times the tissue weight in methanol, two times the tissue weight in water 
into tube 1 and vortex. 
13. Repeat steps 8 and 9. 
14. Leave tube 1 in the fume hood so that the chloroform evaporates for subsequent total 
protein content determination (See Note 21).  
15. Add three times the tissue weight in chloroform and 20 times the tissue weight in 
water into tube 2 and vortex. 
16. Centrifuge tube 2 at 4°C at 1800 x g for 15 minutes. 
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17. Using a pipette, transfer the resulting top layer, i.e. the polar methanol phase, to a new 
cryo-compatible tube, which will be referred to as tube 3 (See Note 20). Keep tube 3 
on ice. 
18. Add six times the tissue weight in water and 1.5 times the tissue weight in methanol 
into tube 2. 
19. Repeat steps 16 and 17.  
20. Freeze tube 2 and tube 3 at -80°C.  
21. Evaporate any chloroform from tube 2 and the methanol and water from tube 3 using 
the lyophilizer as described for cell extracts in subheading 3.2.2, Protocol for freeze-
drying of cell extracts. 
22. Store tube 2, containing the organic phase, and tube 3, containing the polar phase, at -
80°C, or continue with the next steps 
23. For polar cell extracts, prepare the samples for NMR acquisition as described in 
subheading 3.2.2, Protocol for NMR sample preparation of polar cell extracts. 
Protocol for NMR sample preparation of non-polar tissue extracts 
1. Dissolve the samples in 600 µL CDCl3/CD3OD (2:1). 
2. Using a pipette, transfer the solution (600 µL) into 5 mm NMR tubes for NMR 
acquisition. 
3.2.4. Intact tissue 
Although more metabolites can be detected using NMR spectroscopy when analyzing tissue 
extracts, the metabolites detected in intact tissue are less likely to be a product of changes 
other than the innate biological processes of the tumor. The global metabolic profile has been 
found to sustain significant alterations when exposed to elevated temperatures commonly 
used in gas chromatography-mass spectrometry for processes such as derivatization, 
vaporization, and ionization [16]. The degree of chemical degradation of the tissue that the 
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extraction procedure entails, which gives rise to issues similar to the effect of thermal 
degradation, is unknown. 
NMR of solids and semisolids, such as biological tissue, exhibit nuclear interactions that are 
anisotropic, i.e. dependent on the orientation or direction of the molecules which the involved 
nuclei are part of with respect to the external magnetic field. These arise due to the lack of 
molecular mobility [17] and give broad signals that can cause overlap between metabolite 
peaks. The signals may even be so broad that the signal is completely obscured. This does not 
occur when analyzing liquids, since the rapid movement of the molecules averages out the 
anisotropic interactions. Rapid spinning of a solid sample on its axis at an angle of 54.7 
degrees with respect to the external magnetic field, referred to as the magic angle, mimics a 
liquid solution state, where the anisotropy of the interactions is averaged to zero. This method 
is called high resolution magic angle spinning magnetic resonance spectroscopy (HR MAS 
MRS) [18, 19] and produces spectra from tissue samples with resolution that is comparable to 
conventional liquid solution NMR. HR MAS MRS is a non-destructive method, leaving the 
tissue intact for subsequent RNA/DNA/protein extraction or histology [13].  
When preparing samples for HR MAS MRS, these should be kept frozen to minimize tissue 
degradation. For this, an ice block or a nitrogen-filled cooling workstation [11] can be used. 
The following procedure should not exceed five minutes. 
Protocol for intact tissue 
1. Pipette 3.0 µL of sodium formate in D2O solution (See Note 22) into a 30 µL 
disposable insert. Be careful not to make bubbles. 
2. Place the insert on the analytical balance and tare the weight 
3. Place a weighing boat on the ice block or cooling station. 
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4. Cut a frozen sample to fit the insert using a scalpel, biopsy puncher or drill [11] (See 
Section 3.1.2, Protocol for tissue cylinder  drilling from 2 mm whole-mount tissue 
slices) (See Note 23) on a weighing boat. 
5. Transfer the sample carefully into the bottom of the insert using tweezers or the biopsy 
punch. Make sure the content is evenly distributed in the insert (See Note 24).  
6. Weigh the sample in the insert and record the weight. 
7. Introduce a plug into the insert using tweezers. The plug should stay fit at the neck of 
the insert without requiring any further adjustment. 
8. Place a screw cap on the insert and screw tight using the screwdriver (See Note 25).  
9. Set the insert all the way inside a rotor, so that it is fixed and immovable. The 
tightness inside the rotor can be adjusted by tightening or loosening the screw cap with 
the screwdriver. 
10. Introduce a spinning cap upside down into the filling funnel, followed by the upside 
down rotor with the insert. Push the bottom of the rotor gently against the filling 
funnel until a click is heard. 
11. Trace half the diameter of the bottom of the rotor with a black permanent marker to 
enable spin counting.  
12. Store the rotor at -16 °C or lower until transferred into the magnet. 
13. Once NMR acquisition has been completed, the sample can be recovered by using 
liquid nitrogen to loosen the rotor cap and then remove the insert from the rotor. For a 
detailed procedure, we refer to [11]. 
3.3. NMR acquisition 
Prior to NMR spectral acquisition, temperature calibration should be performed to correct for 
any difference between the displayed probe temperature and the true sample temperature. For 
HR MAS MRS acquisition, an additional prior step is the adjustment of the magic angle to 
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optimize the spectral resolution. Although it is not necessary to perform these steps before 
every sample, we suggest doing it at least once a week and when starting the analysis of a new 
batch of samples and/or following insertion of the NMR probe into the magnet. For a detailed 
procedure on magic angle adjustment and temperature calibration for HR MAS MRS, we  
refer to [11]. 
3.3.1. Sample acquisition 
The following is the general procedure for acquiring NMR metabolomics data from in vitro 
and ex vivo samples. For more detailed procedures specific for the analysis of biofluids and 
extracts and for HR MAS MRS of intact tissue, we refer to [20] and [11], respectively: 
Protocol for NMR acquisition 
1. For HR MAS MRS: Load the sample into the magnet and stabilize the spin-rate (see 
Note 26).  
2. Set the temperature to an appropriate value (See Note 27) based on the last 
temperature calibration (See subheading 3.3.) and let stabilize. 
3. For steps 4-10 (See Note 28) 
4. Perform tuning and matching to the nucleus of interest. 
5. Lock on to the solvent signal. 
6. Perform shimming. 
7. Optimize the 90° pulse (P1). 
8. Optimize the value for water suppression (O1). 
9. Acquire the spectrum using the optimal parameters (i.e. shim, P1 and O1) and pulse 
sequences (See subheading 3.3.2.). 
10. For acquisition of biofluids and tissue extracts, see Note 28.  
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3.3.2. Pulse sequences 
The most commonly measured nucleus in NMR spectroscopy is 1H, but other nuclei like 13C, 
31P, 17O, 19F and 23Na can also be utilized in NMR studies. Various NMR pulse sequences are 
available to optimize the acquired spectrum according to the biological questions of interest. 
Arguably the most widely used pulse sequence in NMR metabolomics is the one-dimensional 
Nuclear Overhauser Effect Spectroscopy (NOESY) [21], with which spectra are acquired 
while suppressing the water signal through presaturation. The sequence begins with a long or 
continuous-wave, low-power pulse for presaturation of the water signal. This is followed by 
three high-power 90° pulses where the first and second pulses are separated by a delay, and 
the second and third pulses are separated by a mixing time. The free induction decay (FID), 
i.e. the signal produced by relaxing nuclei [22], is acquired after the third 90° pulse. 
NMR signals from macromolecules, such as lipids and proteins, are broad and can mask 
signals from low-molecular weight metabolites. Because the mobility of small molecules is 
much higher than that of macromolecules, the latter exhibit shorter T2, i.e. faster transverse 
relaxation [22-24]. The difference in T2 can thus be exploited to suppress lipid signals by 
employing T2-weighted pulse sequences which generate NMR spectra where the signal 
intensity of nuclei is directly proportional to its T2. One such sequence is the Carr-Purcell 
Meiboom-Gill (CPMG) pulse sequence, which is particularly useful for lipid suppression in 
serum and tissue spectra. This sequence acts as a T2 filter, suppressing the faster-relaxing 
macromolecules while enhancing the smaller metabolites. It begins with a presaturation and 
90° pulse, similarly to the NOESY sequence. This is followed by a delay and a series of 180° 
pulses, each with a short delay before and after. Each 180° pulse inverts or refocuses the 
signals dephased by the transverse relaxation [22]. The rephasing and subsequent dephasing 
of the signals produces an echo of the original 90° pulse.  
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If instead contrast enhancement of the macromolecules is desired, a diffusion-editing pulse 
sequence can be used. Diffusion-editing pulse gradients provide a diffusion filter which 
excludes signals from the fast-diffusing smaller molecules prior to spectral acquisition. The 
simplest form of a diffusion-edited pulse sequence begins with a 90° pulse followed by a 
gradient to disperse the magnetization, a 180° pulse to invert the dispersed magnetization and 
a second gradient to refocus the signal, prior to the acquisition of the FID [24]. The refocusing 
of signals is inversely proportional to the diffusion coefficient of the molecules they arise 
from, resulting in an attenuation of the faster-diffusing smaller molecules. 
Carbon NMR only detects the 13C isotope whose natural abundance is 1.1%, and since 13C has 
a low gyromagnetic ratio, 13C NMR spectroscopy is less sensitive than 1H NMR spectroscopy. 
Nevertheless, 13C NMR spectroscopy is a valuable tool for investigating fluxes of carbon 
through various metabolic pathways after administration or incubation of 13C labelled 
substrates. The most frequently used one-dimensional 13C NMR pulse sequences are 1H 
decoupled, and these pulse sequences use a repeated set of pulses for continuous irradiation of 
1H. 13C-1H coupled multiplets are consequently collapsed into singlets and enhanced signal-
to-noise ratio is achieved.   
Two-dimensional NMR pulse sequences are particularly useful for the unambiguous 
identification of metabolites. The pulse sequence for J-resolved (JRES) experiments, for 
example, produces a plot of the chemical shift versus the spin-spin coupling constants [25]. 
Comparing this plot to a one-dimensional spectrum allows for the elucidation of the shape and 
number, i.e. multiplicity, of peaks arising at a particular chemical shift. This facilitates 
metabolite assignment and detection of overlapping peaks. The JRES pulse sequence begins 
with a relaxation delay, followed by a 90° pulse with a consecutive incremented mixing time 
(t1) and a 180° pulse also with consecutive t1, prior to the FID acquisition. For a description 
of other two-dimensional NMR experiments for metabolite identification, including chemical 
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shift correlation spectroscopy (COSY), total correlation spectroscopy (TOCSY) and 
heteronuclear single quantum correlation (HSQC) spectroscopy, we refer to [26]. 
3.4. Quantification 
The proportionality of the NMR signal intensity to the number of nuclei producing that signal 
makes NMR spectroscopy highly quantitative. There are several methods available to perform 
quantification of metabolites from NMR spectra. Curve fitting routines, such as PeakFit 
(Systat Software Inc., USA), that determine the area of metabolite peaks, can handle 
overlapping signals. However, this approach can be time consuming as each metabolite peak 
of interest must be fitted manually, and is therefore unfeasible for high numbers of samples 
and untargeted metabolomics approaches. Another peak deconvolution software that is simple 
to use is Chenomx NMR Suite (Chenomx, Edmonton, AB, Canada). Chenomx allows both 
identification and quantification of peaks simultaneously, and can be performed doing both 
manually or semi-automatic adjustment of peaks.  
Another quantification method that has been successfully employed for the quantification of 
ex vivo spectra of prostate tumor tissue [3, 5] is LCModel [27]. This method uses linear 
combinations of spectra of individual metabolites, collectively referred to as a basis set, to fit 
the spectra to be quantified. 
Protocol for peak fitting using LCModel  
1. If a suitable basis set (See Note 29) is not already available, generate a basis set 
through computer simulation of spectra of individual metabolites based on chemical 
shifts and coupling constants [28] using e.g. NMR-SIM (Bruker BioSpin, Germany). 
2. Run LCModel using the graphical user interface (GUI) or in-house scripts and with 
the time domain data of the spectrum to be quantified (See Note 30) and the basis set 
(See Note 31). 
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3. Check the quality of the fit based on the residuals and uncertainties of the 
quantification i.e. Cramer-Rao lower bounds (See Note 32) produced as part of the 
output.   
Relative quantification can be performed automatically by integrating fixed spectral regions 
of metabolites of interest once the spectra are preprocessed, particularly properly aligned. 
Although relative concentrations are not comparable with other studies, they allow 
comparisons between two groups within the same study, similarly as for gene expression 
microarray measurements. An important drawback of peak integration is that areas of 
overlapping peaks cannot be distinguished. This can lead to peak areas being influenced by 
signals other than those belonging to the metabolite of interest. To avoid this, only metabolite 
regions known to be isolated, i.e. not having overlap, should be selected for integration. The 
procedure can be evaluated by visually inspecting the regions selected for integration for each 
spectrum. 
Once the area of the metabolite peaks, i.e. relative concentration, is determined, calculating 
absolute concentration requires a reference signal with known concentration. Deuterated 
trimethylsilyl propionic acid (TSP) [29] formate, or the electronic reference to access in vivo 
concentration (ERETIC) [30] can be used as internal references for the absolute quantification 
of NMR spectra. TSP is more suitable for quantification of biofluids and extracts, as it may 
bind to proteins and other membrane components in tissue, which may lead to overestimation 
of metabolite concentrations [17]. ERETIC is an electronically-simulated reference which can 
be positioned at any region of the spectrum, therefore avoiding reference-analyte interactions 
and peak overlap [31]. Pulse length based concentration (PULCON) [32] is another 
alternative for new spectrometers where the enhanced stability and reproducibility allows 
direct comparison to a standard acquired under identical conditions. Standard curves for 
quantification with PULCON and ERETIC should be established.   
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Protocol for standard curve preparation 
1. Prepare standard solutions for a metabolite, e.g. creatine or formate, in a relevant 
concentration range (See Note 33). 
2. For each concentration value, acquire spectral data for a known amount of standard 
solution (See Note 34) including three technical replicates using the same 
experimental set up, i.e. similar probe, acquisition parameters, etc., as the spectra to be 
quantified. 
3. Calculate the peak area of the standards using the same method used for the spectra to 
be quantified (e.g. PeakFit, Chenomx or LCModel).  
4. Make a standard curve by plotting the concentration versus the peak area for each 
standard solution. 
5. Use the standard curve to relate the peak area to the added number of moles for each 
metabolite to calculate the absolute concentration of the unknown metabolites. 
When absolute quantification is to be performed, it is important to use a sufficiently long 
repetition time (TR) during NMR acquisition, which ideally should be at least 5 times the 
longest T1 to achieve more than 99% of the equilibrium magnetization. If a short TR is used, 
a compensation for this must be implemented for absolute quantification, as described in [33].  
Absolute quantification from spectra acquired using T2-weighted sequences like CPMG can 
also be misleading, as metabolite peak intensities can differ slightly due to variations in T2 
relaxation times rather than just reflecting differences in concentrations [28]. In order to 
ensure accurate absolute quantification based on CPMG spectra, the T2 relaxation effect 
should be calculated and corrected for [34]. 
Protocol for T2 relaxation correction 
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1. For each metabolite to be quantified, repeat NMR spectroscopy experiments with 
different echo times (TE). 
2. Relate each resulting metabolite peak area with the corresponding TE to fit a 
monoexponential decay function representing T2 [34]. 
3. Correct for the T2 effect by multiplying the peak areas by a T2 correction factor (f): f= 
exp[-TEeff/T2], where TEeff is the effective echo time. 
4. Notes 
1. The serum buffer is prepared as follows: i) Dissolve 10.05 g Na2HPO4•7H2O in 380 
mL H2O; ii) add 0.4 g TSP; iii) mix well by ultrasonic mixing; iv) add 5 mL of a 4% 
NaN3/H20 solution; v) adjust pH to 7.4 with 1M HCl (1M NaOH); vi) add H2O until 
total volume is 400 mL; vii) add 100 mL D2O and mix well. 
2. The urine buffer is prepared as follows: i) Dissolve 10.2 g KH2PO4 in 40 mL D2O; ii) 
dissolve 50 mg TSP in 3-5 mL D2O; iii) mix both solutions together by ultrasonic 
mixing; iv) adjust pH to 7.4 with KOH tablets or strong KOD solution (KOH tablets in 
D2O); v) add D2O until total volume is 50 mL and mix well. 
3. The choice of medium depends on the nutrient requirements of the cell line and the 
objective of the experiment. 
4. There are many different ways of isolating serum that are compatible with running an 
NMR experiment. The most important point is that the protocol should be 
standardized for all samples. 
5. Separating the serum sample into several tubes of appropriate volume for analysis is 
recommended to avoid unnecessary freezing-thawing cycles. 
6. Previous studies have reported that the samples can be stored at 4 °C for a maximum 
of  30 days [35] before further processing, but in general, this should be avoided. 
Remix the sample by pipetting before transferring into smaller containers. 
25 
 
7. One side of the biopsy may contain blood and rectal material; cutting off part of the 
ends will reduce the risk of contamination. 
8. Selection of the tissue area to drill out can be based on histopathological evaluation of 
the two adjacent tissue slices collected for clinical pathology. 
9. A 3 mm diameter is recommended for a suitable tissue weight for NMR spectroscopy 
analysis (See Note 23). 
10. Other commonly used fixatives will contaminate the final NMR spectra. 
11. Thawing takes 20-60 minutes, depending on the samples size. 
12. Serum should be pipetted slowly because it is viscous. 
13. It is also possible to analyze intact cells directly using HR MAS MRS (See 
subheading 3.2.4.), but this technique is less developed.   
14. Cells can be incubated with various 13C-enriched substrates. Normally, the substrate 
present in the culture medium is substituted with >99% pure 13C-enriched substrate, to 
maximize the amount of substrate consumed during the experiment. The choice of 
substrate, substrate concentration and incubation time depend on the objective of the 
experiment. 
15. The same extraction protocol can be used for studies of cells cultured under normal 
conditions (i.e. no 13C-enriched tracer). The number of cells needed for high resolution 
1H NMR will be considerably lower. 
16. Incubation duration and condition depend on the choice of 13C substrate. 
17. Total protein content can be determined to help normalize the NMR data to the 
number of cells in the extraction experiment. Alternatively, the cell number can be 
estimated from growth curves or cell counting under identical conditions. 
18. Ideal weight for extraction is 20-50 mg. 
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19. All work with chloroform should be performed in a fume hood and with glass 
material. 
20. Depending on the volume, use a 2 mL or 15 mL cryotube. 
21. Total protein content can be determined for the sample from the pellet in tube 1 after 
dissolving it in NaOH. 
22. Formate is added for shimming purposes and D2O is added to provide a frequency 
lock for the NMR spectrometer. Adding a larger volume than 3 µL of the D2O solution 
can enhance the shimming. Formate can also be used as an internal quantification 
reference. 
23. Ideal weight for intact tissue NMR analysis is 10-15 mg. 
24. The tissue and the formate in D2O solution should be evenly distributed in the insert, 
otherwise it may be difficult to reach the recommended spinning speed of 5000 Hz 
within the magnet. 
25. Do not screw the screw cap too tight, as this will cause the insert neck to expand and 
not fit in the rotor. 
26. 5000 Hz is appropriate when using 600 mHz NMR spectrometers. 
27. The recommended temperature for intact tissue samples is ≤ 5°C to minimize tissue 
degradation. The recommended temperature for serum is 37°C and for urine, cell 
extracts and medium and tissue extracts, it is 27°C. 
28. For biofluids and extracts, the acquisition for samples within the same batch can be 
automated using IconNMR (Bruker BioSpin, Germany). If performed this way, tuning 
and matching, shimming and P1 (90° pulse) optimization is carried out automatically 
for each sample. The O1 (water suppression) value is optimized manually for the first 
sample and set for subsequent samples. 
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29. LCModel requires all peaks observed in the target spectra, including those considered 
irrelevant, e.g. lipids or contaminants, to be comprised in the basis set; a signal that is 
unaccounted for will negatively affect the area calculation for the rest of the peaks in 
the spectrum. For spectra with high degree of lipid peaks, e.g. serum, simulating lipid 
peaks can prove to be a challenge when using this method. 
30. When using in-house scripts, LCmodel prefers the time domain data to be organized 
into a text file of 8 columns containing 4 complex pairs (real, imaginary, real, 
imaginary…) in each row. 
31. Some parameters, including chemical shift range of quantification, number of points 
and references for phasing and frequency alignment, need to be set before running 
LCModel. For more information we refer to the LCModel manual [36]. 
32. Typically a fit with Cramer-Rao lower bounds <15, shown as percentage standard 
deviationin the LCModel output, is considered unsuitable. 
33. Typically solutions with at least five different concentrations are prepared. For 
creatine, these can be 0.25 mM, 1.0 mM, 2.5 mM, 5 mM and 10 mM. 
34. Weigh the amount of sample analyzed using an analytical balance to know the exact 
amount of moles analyzed. 
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